Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial)

NCT ID: NCT06275919

Last Updated: 2025-03-13

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 104 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-09-23
• Study Completion Date: 2027-03-31

Brief Summary

The focus of this study will be to investigate whether Regorafenib demonstrates antitumor activity against recurrent grade II or III meningiomas.

Small trials and case series suggest clinical relevant activity of several VEGF inhibitors such as sunitinib, bevacizumab and valatinib reporting a 6m-PFS rate of 42-64%. Indeed, VEGF and VEGF receptors (VEGFR) are regularly overexpressed in meningiomas and can correlate with outcome.

Regorafenib inhibits angiogenic receptor tyrosine kinases (RTKs) and is highly selective for VEGFR1/2/3; moreover Regorafenib inhibits PDGFRB, FGFR1 and oncogenic intracellular signalling cascades involving c-RAF/RAF1 and BRAF highly expressed in meningiomas.

Noteworthy, Regorafenib showed antitumor activity in vitro and in vivo in a recent study; indeed, Regorafenib showed significant inhibition of meningioma cell motility and invasion and in vivo, mice with orthotopic meningioma xenografts showed a reduced volume of signal enhancement in MRI following Regorafenib therapy; this translated in a significantly increased overall survival time (p<0.05) for Regorafenib treated mice.

Moreover, Regorafenib showed good efficacy in different cancer types, such as colorectal cancer, GIST, hepatocellular carcinoma and glioblastoma (REGOMA trial) , maintainingmaintaining a good quality of life.

Conditions

Meningioma, Malignant

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A (interventional arm)

REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity

Group Type: EXPERIMENTAL

Regorafenib 40 MG Oral Tablet

Intervention Type: DRUG

REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity

Arm B (control arm)

Local Standard of Care until disease progression or unacceptable toxicity

Group Type: ACTIVE_COMPARATOR

Local Standard of Care

Intervention Type: DRUG

In this setting there are not drugs with indication. Every site will treat patients as per their experience.

Interventions

Regorafenib 40 MG Oral Tablet

REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity

Intervention Type: DRUG

Local Standard of Care

In this setting there are not drugs with indication. Every site will treat patients as per their experience.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted
• Patients capable of taking oral medication
• Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
• Histological diagnosis of grade 2 or grade 3 meningioma according to the WHO 2021 classification
• Radiologically documented progression of any existing tumor with an estimated planar growth >25% (bidirectional) in the last 12 months or appearance of new lesions
• Ineligible for further surgery and/or radiotherapy
• at least 1 Measurable lesion (minimum 10 x 10mm) on baseline MRI
• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1 (or KPS ³70)
• Male or female ≥ 18 years of age
• Subjects must have life expectancy of at least 6 months
• Paraffin-embedded tumor tissue available (mandatory)
• Dosage of dexamethasone or equivalent steroid within 7 days prior the randomization ≤4mg/die
• Stable or decreasing dosage of steroids for 7 days prior to the randomization.
• Adequate cardiac function and adequate liver, renal and hematological function
• Subject must have the following laboratory values at screening within 14 days before starting Regorafenib:
• Absolute neutrophil count (ANC) ≥ 1.5 x 109/L without growth factor support for 7 days (14 days if subject received pegfilgrastim).
• Hemoglobin (Hgb) ≥10 g/dL
• Platelet count (plt) ≥100x 109/L
• Serum potassium concentration within normal range, or correctable with supplements
• Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) and serum glutamate pyruvic transaminase (SGPT)/alanine aminotransferase (ALT) ≤ 3.0 x Upper Limit of Normal (ULN).
• Serum total bilirubin ≤ 1.5 x ULN
• Serum creatinine ≤ 1.5 x ULN or measured glomerular filtration rate (GFR) ≥ 50 mL/min/1.73 m2 using an exogenous filtration marker such as iohexol, inulin, 51Cr EDTA or 1125 iothalamate, or creatinine clearance of ≥ 50 mL/min using Cockroft-Gault equation.
• Serum albumin > 3.5 g/dL
• PT (or INR) and APTT within normal range
• For women who are not postmenopausal (i.e., < 2 years after last menstruation) or surgically sterile (absence of ovaries and/or uterus) and who are sexually active: agreement to use an adequate method of contraception (oral contraceptives, intrauterine contraceptive device, or barrier method of contraception in conjunction with spermicidal jelly) during the Treatment period and for at least 6 months after the last dose of study drug.
• For male patients who are partners of premenopausal women: agreement to use a barrier method of contraception during the Treatment period and for at least 6 months after the last dose of study drug.
• Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to participate.
• 19. Patients with measurable, progressive meningioma who received radiation therapy are potentially eligible but need to show evidence of progression at least 24 weeks from completion of radiation therapy.

Exclusion Criteria

• Prior antineoplastic therapy for meningioma
• Subject incapacitated to understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted
• Are taking strong cytochrome P (CYP) CYP3A4 inhibitors (eg, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's Wort)
• Are taking strong UGT1A9 inhibitors (e.g. mefenamic acid, diflunisal and niflumic acid)
• Receiving additional, concurrent, active therapy for Meningioma outside of the trial.
• Disease outside the brain (ie. spinal cord or bone or metastasis to a distant organ)
• Candidate for urgent palliative intervention for primary disease (e.g., impending herniation) as judged by the Investigator
• History of allergy or hypersensitivity to any of the study treatments or any of their excipients.
• In the presence of therapeutic intent to anticoagulate the patient:,INR or PT and aPTT not within therapeutic limits (according to the medical standard in the institution)
• Unable or unwilling to undergo brain MRI scans with intravenous (IV) gadolinium
• History of another malignancy in the previous 3 years, with a disease-free interval of< 3 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible.
• Serious, non-healing wound, ulcer, bone fracture, or abscess.
• Any cerebrovascular accident (including transient ischemic attacks) within the last 6 months prior to initiation of study treatment.
• Have an ongoing infection with severity of Grade 2 or above (CTCAE 5.0)
• Any hemorrhage or bleeding event that is ≥ Grade 3 based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE), Grade 2 intracranial hemorrhage, or persistent thrombotic/embolic event within 4 weeks prior to the start of study medication.
• Uncontrolled or severe cardiac disease (e.g., history of unstable angina, myocardial infarction, coronary stenting, or bypass surgery within the last 6 months prior to initiation of study treatment), symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia (including atrial flutter/fibrillation), requirement for inotropic support or use of devices for cardiac conditions (e.g.,pacemakers/defibrillators), or hypertension (participants with systolic blood pressure[BP] of > 160 mmHg or diastolic BP of > 100 mmHg despite optimal medical management are to be excluded).
• History of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis, or symptomatic pleural effusion.
• Active, known, or suspected auto-immune disease, including systemic lupus erythematosus, Hashimotos thyroiditis, scleroderma, polyarteritis nodosa, or auto-immune hepatitis.
• Known history of hepatitis B, human immunodeficiency virus (HIV), or active hepatitis C infection requiring treatment with antiviral therapy. Note: HIV testing is not required in the absence of clinical suspicion.
• History of bleeding diathesis (irrespective of severity).
• Uncontrolled intercurrent illness including (e.g., symptomatic ascites), but not limited to ongoing or active infection.
• Persistent ≥ Grade 3 Lipase (> 2.0 - 5.0 x upper limit of normal [ULN] with signs or symptoms; > 5.0 x ULN and asymptomatic).
• Persistent proteinuria > 3.5 g/24 hours measured by urine protein creatinine ratio from a random urine sample (≥ Grade 3, CTCAE 5.0)
• Have any malabsorbition condition
• Any condition that could make the subject noncompliant with the study procedures and/or study requirements, as judged by the Investigator (for example: cognitive impairment, psychiatric illness, etc).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bayer

INDUSTRY

Sponsor Role: collaborator

Istituto Oncologico Veneto IRCCS

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Giuseppe Lombardi, MD

Role: PRINCIPAL_INVESTIGATOR

Istituto Oncologico Veneto IOV IRCCS

Locations

IRST Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"

Meldola, Forlì-Cesena, Italy

Site Status: RECRUITING

Azienda Ospedaliera Universitaria Gaetano Martino

Messina, Italia/Messina, Italy

Site Status: NOT_YET_RECRUITING

Humanitas Cancer Center

Rozzano, Milano, Italy

Site Status: RECRUITING

Ospedale San Paolo

Bari, , Italy

Site Status: RECRUITING

Ospedale Bellaria - AUSL Bologna

Bologna, , Italy

Site Status: RECRUITING

Azienda Ospedaliero Universitaria Careggi

Florence, , Italy

Site Status: RECRUITING

Policlinico San Martino

Genova, , Italy

Site Status: RECRUITING

Spedali Riuniti

Livorno, , Italy

Site Status: RECRUITING

Fondazione IRCCS Istituto Neurologico Carlo Besta

Milan, , Italy

Site Status: RECRUITING

IRCCS Ospedale San Raffaele

Milan, , Italy

Site Status: RECRUITING

Ospedale del Mare

Napoli, , Italy

Site Status: RECRUITING

Istituto Oncologico Veneto

Padua, , Italy

Site Status: RECRUITING

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Roma, , Italy

Site Status: NOT_YET_RECRUITING

IRCCS Istituto Tumori Regina Elena

Roma, , Italy

Site Status: RECRUITING

Policlinico Umberto I - Università Sapienza Roma

Roma, , Italy

Site Status: NOT_YET_RECRUITING

A.O.U. Città della Salute e della Scienza di Torino

Torino, , Italy

Site Status: RECRUITING

Countries

Italy

Central Contacts

Gian Luca De Salvo, MD

Role: CONTACT

gianluca.desalvo@iov.veneto.it

049 8215704 ext. +39

Facility Contacts

Lorena Gurrieri, MD

Role: primary

lorena.gurrieri@irst.emr.it

Mariacarmela Santarpia, MD

Role: primary

mariacarmela.santarpia@unime.it

Matteo Simonelli, MD

Role: primary

matteo.simonelli@hunimed.eu

Valeria Internò, MD

Role: primary

valeria.interno@libero.it

Enrico Franceschi, MD

Role: primary

e.franceschi@isnb.it

Isacco Desideri, MD

Role: primary

isacco.desideri@unifi.it

Elisa Bennicelli, MD

Role: primary

elisa.bennicelli@hsanmartino.it

Anna Luisa Di Stefano, MD

Role: primary

annaluisa.distefano@uslnordovest.toscana.it

Paola Gaviani, MD

Role: primary

paola.gaviani@istituto-besta.it

Giulia Berzero, MD

Role: primary

berzero.giulia@hsr.it

Pasqualina Giordano, MD

Role: primary

giopas@email.it

Giuseppe Lombardi, MD

Role: primary

giuseppe.lombardi@iov.veneto.it

Silvia Chiesa, MD

Role: primary

silvia.chiesa@policlinicogemelli.it

Veronica Villani, MD

Role: primary

veronica.villani@ifo.it

Giuseppe Minniti, MD

Role: primary

giuseppe.minniti@uniroma1.it

Roberta Rudà, MD

Role: primary

roberta.ruda@unito.it

References

Bosio A, Cerretti G, Padovan M, Del Bianco P, Polano M, Mandruzzato S, Indraccolo S, Manara R, Librizzi G, Caccese M, Corra M, Maccari M, Lonardi S, De Salvo GL, Lombardi G. Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study). Trials. 2025 Aug 4;26(1):268. doi: 10.1186/s13063-025-08997-2.

Reference Type: DERIVED

PMID: 40759981 (View on PubMed)

Other Identifiers

IOV-BT-1-2023 MIRAGE

Identifier Type: -

Identifier Source: org_study_id